Investor Presentation

• Differentiated lead program SPONTAN/ROXUS with rapid-acting intranasal PDE5 therapy
• Dual U.S. pathway strategy with FDA 505(b)(2) and personalized medicine 503A channels
• Early commercial validation in Australia with 1,000+ prescriptions under TGA Special Access Scheme

LTR Pharma Ltd is a late-stage pharmaceutical company building a portfolio of differentiated specialty therapies. The company's lead program is SPONTAN/ROXUS, a rapid-acting intranasal PDE5 therapy for erectile dysfunction. SPONTAN has demonstrated 5x faster absorption compared to oral PDE5 inhibitors at half the dose, with a validated safety and tolerability profile. LTR Pharma is advancing SPONTAN via the FDA 505(b)(2) regulatory pathway following successful Pre-IND engagement, while also progressing commercial discussions to support a U.S. launch of ROXUS through the personalized medicine (503A) channel. The company has achieved early commercial validation in Australia, with over 1,000 prescriptions under the TGA Special Access Scheme, supporting prescriber adoption and expanding real-world safety and efficacy data. LTR Pharma has strategic partnerships in place with Aptar Pharma, Mayne Pharma, and EBOS/Symbion for co-development, manufacturing, and national distribution. The company is well-funded with $24.1 million in cash and zero debt, enabling it to progress key milestones including the Phase II data readout and continued regulatory and commercial advancement.

LTR Pharma is funded through key milestones, with $24.1 million in cash and zero debt as of March 2026.

LTR Pharma is executing across its clinical, regulatory, and commercial programs, with near-term milestones including completion of human factors and leachables studies, progression of commercial discussions for the U.S. personalized medicine pathway, and advancement of the full Phase II data set and animal toxicology studies to support the Phase III program.